The Oman Investment Authority announced an investment in Neuralink earlier this week. Round size, lead investor, co-investors, and valuation details have not been disclosed yet. OIA’s position is the latest in a sovereign-capital cohort that has been quietly building inside the brain-computer interface (BCI) space for at least the last eighteen months, and a parallel rush is now visible from the tech-billionaire class.

Oman + Neuralink

Oman’s sovereign wealth fund, OIA, holds investments in more than 52 countries and has been steadily increasing its exposure to frontier healthcare technologies. The Neuralink position announced this week fits inside that diversification thesis. It is also a signal that Gulf sovereign capital is now willing to take positions in US-headquartered BCI companies without the backing of a regional development project as cover. The Saudi NEOM-Paradromics partnership a year ago was framed around building a regional hub. The Oman position is just an investment, which is a different kind of statement.

Qatar + Neuralink

Qatar Investment Authority took a stake in Neuralink during the company’s $650 million Series E round in June 2025 at a $9 billion valuation. The Series E disclosed QIA alongside ARK Invest, Sequoia, Founders Fund, and a cluster of US private capital. QIA then placed a second BCI bet in Synchron’s $200 million Series D in November 2025, joining Double Point Ventures, ARCH, Khosla, Bezos Expeditions and the Australian National Reconstruction Fund. Qatar’s strategy of backing frontier US technology has been evident across AI and semiconductors, and neurotechnology is the natural extension. With stakes in two of the four top Western BCI companies, QIA is now the most active sovereign in BCI globally.

Saudi Arabia + Paradromics

Saudi Arabia’s NEOM Investment Fund, a Public Investment Fund subsidiary, led a strategic partnership with Paradromics in February 2025. The investment amount has not been disclosed, but the framing is more ambitious than a typical sovereign equity placement. NEOM and Paradromics committed publicly to building a “premier center for BCI-based healthcare” in the Middle East and North Africa. The Saudi posture is about building physical infrastructure for the BCI category inside the kingdom, not just owning a piece of a US company.

UAE + Neuralink

UAE-linked G42, owned by Mubadala and the Royal Group, also participated in Neuralink’s Series E in June 2025. G42 sits at the intersection of UAE sovereign capital and the Emirati AI strategy that the country has been building since it appointed the world’s first Minister of State for Artificial Intelligence in October 2017. The G42 position in Neuralink connects two pieces of that strategy: artificial intelligence and neural-data acquisition.

Australia + Synchron

Australia’s National Reconstruction Fund Corporation invested AUD 54 million in Synchron in November 2025. NRFC is the federal sovereign vehicle established with a A$15 billion mandate across seven priority areas, including medical science. The Synchron placement is the largest visible Pacific sovereign position in the BCI cohort, and it sits inside Australia’s broader pattern of using NRFC to retain technology leadership in sectors with global commercial potential. Synchron was founded in Melbourne, which gives the placement national-champion overtones.

Europe + INBRAIN

European public capital is concentrated in INBRAIN Neuroelectronics’s $50 million Series B closed in October 2024. Spain’s CDTI-Innvierte and Fond ICO Next Tech are both Spanish state vehicles, and they joined the European Innovation Council’s EIC Fund and Catalonia’s regional Avançsa in that round. Belgium’s imec.xpand, a semi-state spin-out vehicle from the imec research institute, led the financing. INBRAIN now has the densest European public-capital footprint of any BCI company in the world. The round amounted to a coordinated bet by four European public funders on a Barcelona-based graphene neurotechnology company. INBRAIN completed its first-in-human study at Salford Royal Hospital in Manchester earlier this year.

China + the domestic cohort

China runs its own track entirely. The cohort of domestic Chinese BCI players, including Neuracle, NeuroXess, BrainCo, NeuCyber, and StairMed, sits inside a state-backed framework that includes the 2026 Government Work Report’s strategic priority designation, the China Brain Project, NMPA expedited pathways, the new Order 818 commercialisation framework that took effect on 1 May 2026, and provincial reimbursement pricing rolling out across Sichuan, Hubei, and Zhejiang. China is not investing in BCI as a portfolio diversification play. It is building a domestic BCI industrial base inside its industrial-builder posture, and foreign-invested enterprises face significant restrictions and grey-area compliance risk under the Order 818 pathway, with the 2024 Foreign Investment Negative List continuing to prohibit foreign investment in adjacent cell and gene therapy categories outside designated free trade zones.

The tech-billionaire class is also racing in

Unlike sovereign capital, which is buying strategic infrastructure exposure for the next two decades, tech-billionaire capital is buying optionality on whatever neural-data the AI era ends up needing. BCIs will provide much-needed multi-dimensional data sets for training AI models, beyond the audio and visual data current models rely on today.

The result is a heavy concentration of tech wealth across BCI companies.

• Sam Altman. Co-founded Merge Labs to compete directly with Neuralink. OpenAI led Merge’s $252 million seed round in January 2026 at an $850 million valuation, writing the largest single cheque.
• Elon Musk. Owns Neuralink and runs xAI. The data-pipeline implications of an AI company and a BCI company under common ownership are exactly what they look like.
• Bill Gates. In Synchron through Gates Frontier, since the company’s $75 million Series C in December 2022.
• Jeff Bezos. In Synchron through Bezos Expeditions, which participated in the same Series C and the subsequent $200 million Series D.
• Mark Cuban. An estimated $8 million to $10 million into Synaptrix Labs’s late 2025 seed round, a New York-based wearable EEG company building wheelchair-control interfaces for paralysed users.
• Vinod Khosla. In Synchron (which Khosla Ventures led at Series B in 2021), Science Corporation, and Sabi.
• Peter Thiel. In Neuralink through Founders Fund.

Apple + Synchron

Apple bypassed equity entirely. The company announced a Brain-Computer Interface Human Interface Device protocol on 13 May 2025, integrating BCI input as a native class across iOS, iPadOS, and visionOS. Synchron was the first BCI company to integrate with the protocol, and the first public demonstration came in August 2025 with a COMMAND-trial participant living with ALS controlling an iPad with thought alone. Apple has not taken an equity position in any BCI company. The OS-layer integration is a different mode of positioning. It pre-positions Apple as the consumer-side endpoint of the BCI category whatever the eventual hardware winner is, without writing a venture cheque.

Forward Radar

Several major sovereign players are conspicuously absent from the BCI capital stack. Singapore’s Temasek and GIC, Norway’s NBIM, South Korea’s KIC, France’s Bpifrance, and Bahrain’s Mumtalakat are all active in adjacent frontier categories like AI, biotech, and semiconductors, but none has yet placed a visible BCI bet. South Korea’s K-Moonshot mission and Thailand’s $15 billion AI and quantum push are operating at the state-program level rather than via direct sovereign equity. Thailand has separately built a corporate BCI commercial corridor through C.P. Group’s positioning across Axoft and OYMotion. India is similarly absent. NIIF, LIC, and EPFO are all major Indian state-aligned investors operating across global tech and biotech, but none has placed a visible BCI position despite India hosting active BCI ecosystem players including Motorica India and the closed-loop clinical research programmes at IIT Kanpur.

The next major raises in the cohort will test whether any of them land. Synchron is moving toward a Series E, Paradromics has follow-on capacity after the NEOM partnership, and INBRAIN will need a Series C to fund pivotal trials.

On the US side, the country’s largest institutional LPs (CalPERS, NYSCRF, the Texas Teachers’ fund, and New York Common) have no visible BCI placements either. The US BCI capital base is venture and tech-billionaire money, not pension or state-LP capital. Whether US institutional LPs follow Australia’s NRFC into a federal-sovereign BCI position is a different but parallel question.

Google and Anthropic have not yet placed visible BCI bets either, and when they follow OpenAI and the Musk-Altman axis into the field is likely only a question of time.

Counter-weights and active risks

The rush is not without counter-weights. Foreign investment screening regimes (CFIUS in the US, FIRB in Australia, the EU foreign-subsidies framework) were designed for semiconductor and defence categories and have not yet been formally extended to cover sovereign equity in neural-interface companies. The clinical-stage pipeline is still small, with most companies operating first-in-human studies in single-digit patient counts, and long-term safety, bandwidth, and decoder-stability claims remain unproven at population scale. Neural-data sovereignty, the consent architecture for thought decoding, and the cross-border export controls implied by Chinese state-aligned BCI capital flowing into Western markets are all unsettled questions. Any of these can convert from latent risk to active gating event inside the next eighteen months.

The category has already attracted over $1 billion in capital in 2026 alone, and the global rush to access the brain will only accelerate from here.

What this means for enterprise and regulators

BCI has crossed from speculative venture territory into strategic infrastructure. The category now runs well beyond healthcare, into consumer technology, education, the workplace, and defence.

With sovereign and big tech capital rushing in well ahead of finalised regulatory frameworks, how should enterprises and policymakers position themselves? The Spring 2026 Dargentic Intelligence Report, Brain-Computer Interfaces, The Takeoff Era, addresses this trajectory in depth. Early signs already indicate where commercial value will accrue and how regulatory architectures will take shape. The full Spring 2026 issue is available at dargentic.com/reports.

Sources: Oman Investment Authority backs Neuralink — Zawya, 8 May 2026. Paradromics × NEOM Investment Fund — CNBC, 12 February 2025. NRFC AUD 54 million in Synchron — National Reconstruction Fund Corporation. QIA in Neuralink Series E — TSG Invest investor profile. INBRAIN Series B with EIC Fund, CDTI-Innvierte, Fond ICO and Avançsa — imec, 29 October 2024. Mark Cuban backs Synaptrix Labs — citybiz. Apple BCI HID protocol with Synchron — BusinessWire, 13 May 2025. QIA in Synchron Series D — Bloomberg, 6 November 2025.